Skip to main content
. Author manuscript; available in PMC: 2016 Oct 12.
Published in final edited form as: JAMA Dermatol. 2015 Nov;151(11):1206–1212. doi: 10.1001/jamadermatol.2015.1916

Figure 2. Grade 3 Cutaneous Adverse Events in a Patient Treated With Pembrolizumab.

Figure 2

A, Macular papular eruption with predilection sites on photoexposed areas of the chest. B, Macular papular eruption with predilection sites on photoexposed areas of the arm.